AI Analysis AI Analysis of NVO AI-Powered Market Insights
Stock Analysis PRO New!
Risk Assessment PRO New!
Trading Strategy PRO New!
Add NVO to Watchlist?
Some Reasons Why To Add NVO:
  • High gross margin of 81.8%
  • Strong operating margin of 45.3%
  • Healthy interest coverage ratio of 29.1x
PDF

Novo Nordisk A/S stock upgraded to Buy Candidate
(Updated on Jul 21, 2026)

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Buy or Hold candidate since Jun 22, 2026 Gain 7.58%

The Novo Nordisk A/S stock price fell by -0.464% on the last day (Tuesday, 21st Jul 2026) from $49.61 to $49.38. It has now fallen 3 days in a row. During the last trading day the stock fluctuated 1.80% from a day low at $48.95 to a day high of $49.83. The price has fallen in 7 of the last 10 days and is down by -0.52% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -1 million shares and in total, 6 million shares were bought and sold for approximately $281.68 million.

The stock lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 17.79% during the next 3 months and, with a 90% probability hold a price between $52.70 and $61.09 at the end of this 3-month period.

NVO Signals & Forecast

The Novo Nordisk A/S stock holds a sell signal from the short-term Moving Average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term Moving Average at approximately $49.96. On a fall, the stock will find some support from the long-term average at approximately $46.61. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Thursday, July 16, 2026, and so far it has fallen -4.08%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss for Novo Nordisk A/S stock

On the downside, the stock finds support just below today's level from accumulated volume at $45.76 and $44.39. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Novo Nordisk A/S finds support just below today's level at $45.76. If this is broken, then the next support from accumulated volume will be at $44.39 and $43.90.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.88 between high and low, or 1.80%. For the last week, the stock has had daily average volatility of 2.37%.

Our recommended stop-loss: $46.79 (-5.25%) (This stock has medium daily movements and this gives medium risk. There is a sell signal from a pivot top found 3 days ago.)

Trading Expectations (NVO) For The Upcoming Trading Day Of Wednesday 22nd

For the upcoming trading day on Wednesday, 22nd we expect Novo Nordisk A/S to open at $49.39, and during the day (based on 14 day Average True Range), to move between $48.75 and $50.01, which gives a possible trading interval of +/-$1.25 (+/-2.57%) up or down from last closing price. If Novo Nordisk A/S takes out the full calculated possible swing range there will be an estimated 2.57% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $49.64 (0.53%) than the support at $45.76 (7.33%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Novo Nordisk A/S stock A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Novo Nordisk A/S stock to perform well in the short-term. We have upgraded our analysis conclusion for this stock since the last evaluation from a Hold to a Buy candidate.

Current score: 1.013 Buy Candidate Upgraded

Predicted Fair Opening Price

Predicted fair opening price on July 22, 2026 - $49.39 ( 0.0135%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* eToro
*Your capital is at risk

NVO Performance

Trading levels for NVO

StockInvest.us
Full Access. No Commitment. 7 Days Free!
Long & Short-Term Golden Star Lists
AI Stock Analysis*
Top 10 Candidates on Every List
Premium Lists
Ad-FREE Browsing
Advanced Stock Screener

Fibonacci Support & Resistance Levels

Level Price
R3 50.27 1.80%
R2 49.93 1.11%
R1 49.72 0.694%
Price 49.38
S1 49.05 -0.667%
S2 48.84 -1.09%
S3 48.51 -1.77%

Accumulated Volume Support & Resistance Levels

Level Price
R3 50.56 2.39%
R2 50.43 2.13%
R1 49.64 0.527%
Price 49.38
S1 45.76 -7.33%
S2 44.39 -10.11%
S3 43.90 -11.10%

NVO Dividend Payout History


# Declaration Date Ex-Date Pay Date Amount Yield
1 Feb 04, 2026 Mar 30, 2026 Apr 08, 2026 $0.92 1.92%
2 Sep 18, 2025 Sep 18, 2025 Sep 29, 2025 $0.0038 0.0067%
3 Aug 18, 2025 Aug 18, 2025 Aug 26, 2025 $0.412 0.84%
4 Feb 05, 2025 Mar 31, 2025 Apr 08, 2025 $0.787 1.28%
5 Aug 16, 2024 Aug 16, 2024 Aug 26, 2024 $0.374 0.277%

FAQ

What is the symbol for Novo Nordisk A/S Stock and on which exchange is it traded?
The symbol for Novo Nordisk A/S is NVO and it is traded on the NYSE (New York Stock Exchange).

Should I buy or sell Novo Nordisk A/S Stock?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Novo Nordisk A/S stock to perform well in the short-term. We have upgraded our analysis conclusion for this stock since the last evaluation from a Hold to a Buy candidate.

How to buy Novo Nordisk A/S Stock?
Novo Nordisk A/S Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Novo Nordisk A/S Stock.

What's the current price of Novo Nordisk A/S Stock?
As of the end of day on the Jul 21, 2026, the price of an Novo Nordisk A/S (NVO) share was $49.38.

What is the 52-week high and low for Novo Nordisk A/S Stock?
The 52-week high for Novo Nordisk A/S Stock is $71.80 and the 52-week low is $35.13.

What is the market capitalization of Novo Nordisk A/S Stock?
As of the Jul 21, 2026, the market capitalization of Novo Nordisk A/S is 219.434B.

When is the next earnings date for Novo Nordisk A/S?
The upcoming earnings date for Novo Nordisk A/S is Aug 05, 2026.
Click to get the best stock tips daily for free!
ABOUT NOVO NORDISK A/S
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the ...
GOLDEN STAR
Ticker Change Signal Date
DHT
$17.31
3.35% Jul 13
JLL
$299.78
8.73% Jun 24
NMRK
$15.02
3.26% Jun 24
NESR
$25.07
8.62% Jun 23
CAG
$13.43
9.20% Jun 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE